Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

References

• Kumar SK, Rajkumar SV, Dispenzieri A, et al Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R, et al Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518–521.
   PubMed Web of Science ®Google Scholar
• Reece D, Song KW, Fu T, et al Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522–525.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Soulier J, Fermand JP, et al Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010;24:623–628.
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41–49.
   PubMed Web of Science ®Google Scholar
• Taniwaki M, Nishida K, Takashima T, et al Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 1994;84:2283–2290.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD, Zhan F, Burington BE, et al A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;15:2276–2284.
   Web of Science ®Google Scholar
• Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10:117–126.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, et al Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724–1732.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Trieu Y, et al Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006;135:486–491.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ, et al Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006;20:2034–2040.
   PubMed Web of Science ®Google Scholar
• Nemec P, Zemanova Z, Greslikova H, et al Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010;16:548–554.
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, Jiang NN, Xu W, Reece D. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma: adverse effect of 1q21 gains. Leuk Res. 2010 May 25. [Epub ahead of print].
   Google Scholar
• Chang H, Ning Y, Qi X, Yeung J, Xu W. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 2007;139:51–54.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Jiang A, Xu W, Young T, Reece T. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010;45:117–121.
   PubMed Web of Science ®Google Scholar
• Chen C, Reece DE, Siegel D, et al Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009;146:164–170.
   PubMed Web of Science ®Google Scholar
• Chang H, Li D, Zhuang L, et al Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004;45:965–969.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R, et al Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546–1558.
   PubMedGoogle Scholar
• Fonseca R, Bergsagel PL, Drach J, et al International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210–2221.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, et al Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Dewald GW, Therneau T, Larson D, et al Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of multiple myeloma. Blood 2005;106:3553–3558.
   PubMed Web of Science ®Google Scholar
• Xiong W, Wu X, Starnes S, et al An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235–4246.
   PubMed Web of Science ®Google Scholar
• Reece DE, Trieu Y, Chang H, et al Treatment of relapsed and refractory multiple myeloma in patients with p53 deletion. Blood 2008;112(Suppl. 1): Abstract 1724.
   Google Scholar
• Leone PE, Walker BA, Jenner MW, et al Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008;14:6033–6041.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Gertz MA, Chung TH, et al Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31–32 deletion as a prognostic factor in myeloma. Leukemia. 2010;24:833–842.
   PubMed Web of Science ®Google Scholar